Abstract: The present disclosure relates to a novel substituted pyrazole derivative having an effect of inhibiting serine/threonine kinase activity targeting receptor ALK5 of TGF-?, and a pharmaceutical composition including the compound of the present disclosure as an active ingredient may be useful in preventing and/or treating cancers, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, pulmonary diseases, cardiovascular diseases or metabolic diseases, or other diseases associated with a decrease in TGF family signaling activity.

Abstract: A content sharing method includes: selecting, by a content sharing terminal, content; transmitting, by the content sharing terminal, identification information of the selected content to an external device; and reproducing, by the content sharing terminal, the selected content while the external device is reproducing the selected content based on the identification information.

Abstract: The device for cooperation control of the EMS and the DMS comprises: a calculation unit for calculating an AQI index on the basis of target system information and power flow calculation data; a determination unit which determines whether or not to perform reactive power cooperation control switching of the DMS on the basis of the calculated AQI index and the amount of needed local reserve reactive power (Qreq), and which determines a suppliable reactive power capacity on the basis of the amount of needed local reserve reactive power (Qreq) and a suppliable reactive power range; and a control unit which transmits a cooperation control mode switching control signal so as to switch the DMS to a reactive power cooperation control mode if it is determined that reactive power cooperation control switching of the DMS is to be performed, and which controls the DMS to supply reactive power.

Abstract: The present invention relates to a novel bicyclic derivative that has an inhibitory activity against sodium-glucose linked transporters (SGLTs) present in the intestines and kidneys, or a pharmaceutically acceptable salt, isomer, hydrate or solvate thereof, and a pharmaceutical composition including the same as an active ingredient, which effectively inhibit the SGLT activity, and thus can be used as a therapeutic agent to treat diseases caused by hyperglycemia, such as diabetes including insulin-dependent diabetes (type I diabetes mellitus) and non-insulin-dependent diabetes (type II diabetes mellitus), diabetic complications, and obesity.

Abstract: A content sharing method includes: selecting, by a content sharing terminal, content; transmitting, by the content sharing terminal, identification information of the selected content to an external device; and reproducing, by the content sharing terminal, the selected content while the external device is reproducing the selected content based on the identification information.

Abstract: The present invention relates to an apparatus for managing voltage stability of an electrical power grid and a method therefor.

Abstract: The present invention relates to a novel bicyclic derivative that has an inhibitory activity against sodium-glucose linked transporters (SGLTs) present in the intestines and kidneys, or a pharmaceutically acceptable salt, isomer, hydrate or solvate thereof, and a pharmaceutical composition including the same as an active ingredient, which effectively inhibit the SGLT activity, and thus can be used as a therapeutic agent to treat diseases caused by hyperglycemia, such as diabetes including insulin-dependent diabetes (type I diabetes mellitus) and non-insulin-dependent diabetes (type II diabetes mellitus), diabetic complications, and obesity.

Abstract: A display apparatus and a method of controlling the display apparatus are provided. The display apparatus includes a display, a communication unit, and a processor. The display is configured to display content. The communication unit is configured to communicate with an external apparatus and a remote controller. When the communication unit receives a first signal corresponding to a user command being received at the remote controller, the processor controls the communication unit to transmit to the external apparatus a second signal comprising the user command and context information regarding the content. In response to receiving, from the external apparatus, application information which indicates an application to be executed, the processor executes the application.

Abstract: The present invention relates generally to the field of molecular biology and concerns a method for enhancing yield-related traits in plants by modulating expression in a plant of a nucleic acid encoding an SGT1 polypeptide, or a CLC-pKG polypeptide, or a HD-hydrolase-like polypeptide. The present invention also concerns plants having modulated expression of a nucleic acid encoding an SGT1 polypeptide, or a CLC-pKG polypeptide, or a HD-hydrolase-like polypeptide, which plants have enhanced yield-related traits relative to corresponding wild type plants or other control plants. The invention also provides constructs useful in the methods of the invention.

Abstract: The present invention relates generally to the field of molecular biology and concerns a method for enhancing yield-related traits in plants by modulating expression in a plant of a nucleic acid encoding an SGT1 polypeptide, or a CLC-pKG polypeptide, or a HD-hydrolase-like polypeptide. The present invention also concerns plants having modulated expression of a nucleic acid encoding an SGT1 polypeptide, or a CLC-pKG polypeptide, or a HD-hydrolase-like polypeptide, which plants have enhanced yield-related traits relative to corresponding wild type plants or other control plants. The invention also provides constructs useful in the methods of the invention.

Abstract: Provided are a thieno[3,2-d]pyrimidine derivative of formula (I) or a pharmaceutically acceptable salt thereof having inhibitory activity for protein kinase, and a pharmaceutical composition comprising same for prevention and treatment of abnormal cell growth diseases.

Abstract: The device for cooperation control of the EMS and the DMS comprises: a calculation unit for calculating an AQI index on the basis of target system information and power flow calculation data; a determination unit which determines whether or not to perform reactive power cooperation control switching of the DMS on the basis of the calculated AQI index and the amount of needed local reserve reactive power (Qreq), and which determines a suppliable reactive power capacity on the basis of the amount of needed local reserve reactive power (Qreq) and a suppliable reactive power range; and a control unit which transmits a cooperation control mode switching control signal so as to switch the DMS to a reactive power cooperation control mode if it is determined that reactive power cooperation control switching of the DMS is to be performed, and which controls the DMS to supply reactive power.

Abstract: Provided are a thieno[3,2-d]pyrimidine derivative of formula (I) or a pharmaceutically acceptable salt thereof having inhibitory activity for protein kinase, and a pharmaceutical composition comprising same for prevention and treatment of abnormal cell growth diseases.

Abstract: Provided is a pharmaceutical composition comprising, as an active ingredient, a quinoline or quinazoline derivative of formula (I), a pharmaceutically acceptable salt, an isomer, a hydrate, and a solvate thereof, which is effective in the prevention and treatment of a cancer, inflammation, autoimmune diseases or neurodegenerative disorders which are induced by the overexpression of inhibitor of apoptosis proteins (IAPs).

Abstract: A mobile terminal to provide an interface for user information management includes a display to display a user interface to receive a user input and to receive the user input via the displayed user interface, a wireless transceiver to establish a voice communication channel and to transceive a voice communication signal, and a controller to determine an event for communicating user information and to control the user interface to display the user information. The user information is communicated via the established voice communication channel.

Abstract: Provided is a pharmaceutical composition comprising, as an active ingredient, a quinoline or quinazoline derivative of formula (I), a pharmaceutically acceptable salt, an isomer, a hydrate, and a solvate thereof, which is effective in the prevention and treatment of a cancer, inflammation, autoimmune diseases or neurodegenerative disorders which are induced by the overexpression of inhibitor of apoptosis proteins (IAPs).

Abstract: The present invention relates generally to the field of molecular biology and concerns a method for enhancing yield-related traits in plants by modulating expression in a plant of a nucleic acid encoding an SGT1 polypeptide, or a CLC-pKG polypeptide, or a HD-hydrolase-like polypeptide. The present invention also concerns plants having modulated expression of a nucleic acid encoding an SGT1 polypeptide, or a CLC-pKG polypeptide, or a HD-hydrolase-like polypeptide, which plants have enhanced yield-related traits relative to corresponding wild type plants or other control plants. The invention also provides constructs useful in the methods of the invention.

Abstract: Methods for enhancing various economically important yield-related traits in plants by modulating expression in a plant of a nucleic acid encoding a LEJ1 (Loss of timing of ET and JA biosynthesisI) polypeptide, ExbB polypeptide, NMPRT (nicotinamide phosphoribosyltransferase) polypeptide, AP2-26-like polypeptide or HD8-like polypeptide are provided. Plants produced by the methods are also provided, which have enhanced yield-related traits relative to corresponding wild type plants or other control plants. Constructs comprising a nucleic acid encoding a LEJ1, ExbB, NMPRT, AP2-26-like or HD8-like polypeptide and uses thereof are provided.

Abstract: Disclosed are peptides having SEQ ID NOs: 1 to 24 that induce superoxide generation by human monocytes or neutrophils; that induce an intracellular calcium increase by human peripheral blood monocytes or neutrophils; binds to formyl peptide receptor or formyl peptide receptor-like 1; that induce chemotactic migration of human monocytes or neutrophils in vitro; that induce degranulation in formyl peptide receptor expressing cells or formyl peptide receptor-like 1 expressing cells; that stimulate extracellular signal regulated protein kinase phosphorylation via activation of formyl peptide receptor or formyl peptide receptor-like 1; or that stimulate Akt phosphorylation via activation of formyl peptide receptor or formyl peptide receptor-like 1.

Abstract: Provided are a thieno[3,2-d]pyrimidine derivative of formula (I) or a pharmaceutically acceptable salt thereof having inhibitory activity for protein kinase, and a pharmaceutical composition comprising same for prevention and treatment of abnormal cell growth diseases.